rese-cel

Generic: resecabtagene autoleucel·Code: CABA-201

rese-cel: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

Company	Phase	Indication
Cabaletta Bio, Inc. (CABA)	Phase 2	Dermatomyositis, anti-synthetase syndrome, systemic lupus er...

FDA Decisions

FDA_MeetingInitiated FDA-aligned dermatomyositis (DM) and antisynthetase syndrome (ASyS) registrational cohort in Dec 2025 to evaluate 17 patients (expanded to enroll ~14 DM patients).(CABA)

FDA_MeetingFDA alignment was reached on registrational cohorts for Rese-cel in myositis.(CABA)

Frequently asked questions

Who is developing rese-cel?

rese-cel is being developed by Cabaletta Bio, Inc..

What is rese-cel's latest FDA decision?

The most recent tracked FDA decision for rese-cel is FDA_Meeting for Initiated FDA-aligned dermatomyositis (DM) and antisynthetase syndrome (ASyS) registrational cohort in Dec 2025 to evaluate 17 patients (expanded to enroll ~14 DM patients)..

Get deeper analysis on rese-cel

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis